Crataegus-Spezialextrakt WS® 1442 hemmt die Sekretion von Apolipoprotein B100 (ApoB) und erhöht die Transkription des Low-Density Lipoproteinrezeptors (LDL-R) in humanen HepG2-Zellen

Koch, E.; Lanzendörfer-Goossens, H.; Weibezahn, C.

doi:10.1055/s-2006-954919

Search citation statements

Order By: Relevance

Paper Sections

Select...

Lipid Metabolism1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

2017

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The extract also downregulated ApoB synthesis in a concentration-dependent manner. ApoB is a structural component of serum LDL particles, and also a competitive ligand of LDL-R, which is in turn responsible for binding serum LDL for elimination by receptor-mediated uptake [37].…”

Section: Lipid Metabolismmentioning

confidence: 99%

Standardized Extracts from Hawthorn Leaves and Flowers in the Treatment of Cardiovascular Disorders – Preclinical and Clinical Studies

Koch

Malek

2011

Planta Med

View full text Add to dashboard Cite

show abstract

Section: Lipid Metabolismmentioning

confidence: 99%

Standardized Extracts from Hawthorn Leaves and Flowers in the Treatment of Cardiovascular Disorders – Preclinical and Clinical Studies

Koch

Malek

2011

Planta Med

View full text Add to dashboard Cite

show abstract

Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review

Holubarsch

Colucci

Eha

2017

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

Preparations from Crataegus (hawthorn) have a long history in the treatment of heart failure. WS 1442 is a dry extract from hawthorn leaves with flowers (4–6.6:1), extraction solvent of ethanol 45% (w/w), adjusted to 17.3–20.1% of oligomeric procyanidins. Nonclinical studies show that WS 1442 has positive inotropic and antiarrhythmic properties and protects the myocardium from ischemic damage, reperfusion injury, and hypertension-related hypertrophy, improves endothelial functions such as NO synthesis, and delays endothelial senescence. Randomized, controlled trials in patients with heart failure have demonstrated that the herbal medicinal product increases functional capacity, alleviates disabling symptoms, and improves health-related quality of life, all of which have become important targets of heart failure therapy according to current disease management guidelines. Clinical trials (including a 2-year mortality study with polypharmacy and > 1300 patients exposed) and post-marketing surveillance studies have shown that WS 1442 has a very favorable safety profile both as monotherapy and as add-on therapy, where no drug interactions have been observed. No specific adverse reactions to WS 1442 are known to date. WS 1442 may thus help to close the therapeutic gap between systolic and diastolic heart failure for which evidence of efficacy for other cardioactive drugs is sparse. Scientific evidence shows that WS 1442 is safe and has a beneficial effect in patients with heart failure corresponding to New York Heart Association classes II or III. The benefit-risk assessment for WS 1442 is therefore positive.

show abstract

Crataegus-Spezialextrakt WS® 1442 hemmt die Sekretion von Apolipoprotein B100 (ApoB) und erhöht die Transkription des Low-Density Lipoproteinrezeptors (LDL-R) in humanen HepG2-Zellen

Cited by 2 publications

References 0 publications

Standardized Extracts from Hawthorn Leaves and Flowers in the Treatment of Cardiovascular Disorders – Preclinical and Clinical Studies

Standardized Extracts from Hawthorn Leaves and Flowers in the Treatment of Cardiovascular Disorders – Preclinical and Clinical Studies

Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review

Contact Info

Product

Resources

About